Cellectis S.A. (CLLS) Cash Flow Statement

The extreme volatility in the conversion of net income to cash suggests that reported earnings are heavily influenced by accounting recognition of partnership milestones rather than core business performance. Investors should interpret these figures with caution, as the lack of a consistent positive correlation between income and cash flow indicates that the company's earnings quality remains fundamentally strained.

The sporadic positive FCF quarters appear to be outliers driven by large, one-time working capital inflows rather than organic operational improvements. This trajectory suggests that the company remains in a capital-intensive phase where cash burn is the primary operational reality, necessitating ongoing external financing to maintain its clinical programs.

These large, lumpy working capital movements indicate that the company lacks a predictable cash conversion cycle. The reliance on these inflows to offset operating losses implies that any delay in milestone achievement could lead to immediate liquidity pressure, warranting close monitoring of accounts receivable and deferred revenue balances.

While the company has invested in its own manufacturing facilities, the relatively modest CapEx figures suggest that the bulk of its capital is consumed by clinical trial costs and personnel rather than asset-heavy expansion. This implies that the company's financial risk is tied more to the success of its clinical programs than to the maintenance of its physical asset base.